AbbVie Inc (ABBV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AbbVie Inc (ABBV) has a cash flow conversion efficiency ratio of -1.616x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.22 Billion) by net assets ($-3.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ABBV net asset quality score to measure how much of total assets are equity-financed.
AbbVie Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how AbbVie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AbbVie Inc (ABBV) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
AbbVie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbbVie Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chevron Corp
NYSE:CVX
|
0.013x |
|
Caterpillar Inc
NYSE:CAT
|
0.168x |
|
Lam Research Corp
NASDAQ:LRCX
|
0.108x |
|
Oracle Corporation
NYSE:ORCL
|
0.340x |
|
The Coca-Cola Company
NYSE:KO
|
0.057x |
|
GE Aerospace
NYSE:GE
|
0.100x |
|
HSBC Holdings plc
MX:HBCN
|
N/A |
|
Procter & Gamble Company
NYSE:PG
|
0.093x |
Annual Cash Flow Conversion Efficiency for AbbVie Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of AbbVie Inc from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see ABBV market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.23 Billion | $19.03 Billion | -5.895x | -205.45% |
| 2024-12-31 | $3.36 Billion | $18.81 Billion | 5.590x | +154.49% |
| 2023-12-31 | $10.40 Billion | $22.84 Billion | 2.197x | +52.24% |
| 2022-12-31 | $17.29 Billion | $24.94 Billion | 1.443x | -2.22% |
| 2021-12-31 | $15.44 Billion | $22.78 Billion | 1.476x | +9.88% |
| 2020-12-31 | $13.10 Billion | $17.59 Billion | 1.343x | +182.36% |
| 2019-12-31 | $-8.17 Billion | $13.32 Billion | -1.630x | -2.56% |
| 2018-12-31 | $-8.45 Billion | $13.43 Billion | -1.590x | -181.35% |
| 2017-12-31 | $5.10 Billion | $9.96 Billion | 1.954x | +28.66% |
| 2016-12-31 | $4.64 Billion | $7.04 Billion | 1.519x | -20.48% |
| 2015-12-31 | $3.94 Billion | $7.54 Billion | 1.910x | -6.25% |
| 2014-12-31 | $1.74 Billion | $3.55 Billion | 2.037x | +46.03% |
| 2013-12-31 | $4.49 Billion | $6.27 Billion | 1.395x | -26.05% |
| 2012-12-31 | $3.36 Billion | $6.34 Billion | 1.887x | +260.37% |
| 2011-12-31 | $11.93 Billion | $6.25 Billion | 0.524x | +65.22% |
| 2010-12-31 | $15.70 Billion | $4.98 Billion | 0.317x | -- |
About AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more